MMIT Announces 2020 Directory of Health Plans
Getting accurate payer and health plan enrollment data in a timely fashion is difficult; understanding the impact of health plan [...]
Deomcrats Take Pharma Executives to Task Over Excessive Price Hikes
Pharma industry executives have long justified increasing drug prices by pointing out the costs and risks of research and the [...]
Hospitals and Outpatient Care Are the Primary Drivers of Sky-high US Healthcare Costs
Although drug prices are at the forefront of many voters’ minds, they are not actually the main reason the U.S. [...]
Celgene Accused of Gouging on Revlimid Price
A congressional probe headed by the House Committee on Oversight and Government Reform released a scathing 45 page report detailing [...]
[Webinar] Towards Greater Diversity in Clinical Trials and Health Plan Networks
Join HealthVerity on Thursday, October 15th, 2020 at 12:00 PM EDT for an in-depth discussion on the challenges of recruiting [...]
Private Payers Lead Charge Toward Value-Based Care
Xtelligent Healthcare media has revealed results from a new survey showing that private payers are more likely than public payers [...]
SCOTUS Pick Threatens Value-based Care
The Senate is moving quickly to confirm a conservative replacement for the Supreme Court in the next month, leaving the [...]
HealthVerity acquires Curisium
In July, HealthVerity, acquired the industry’s leading innovator in cloud-based drug rebate processing and contract performance management, Curisium. As a [...]
Congressional Probe Turns Up Heat on Teva
According to a new congressional report, Teva repeatedly raised prices on its lucrative multiple sclerosis drug Copaxone for years, using [...]
Access Market Intelligence Launches New Specialty Pharmacy Database
Today, Access Market Intelligence (AMI), announced the launch of its Specialty Pharmacy Database (SPD) which provides the industry’s most comprehensive, [...]
EU Provides Guidance On Using Registry Studies As RWE Source
A new guideline drafted in the EU explains how disease registries can help supplement pre-authorization evidence and provide infrastructure for [...]
Reality Check for Real-World Evidence
How do real-world data such as those mined from EHRs match up to that of randomized clinical trials? Supporters of [...]
[Webinar] Faster Science: HEOR, RWE & Market Access Sourcing
Do you wish you could get HEOR, RWE and Market Access projects started faster, cheaper, & using the most optimal [...]
Aetion Launches Population Level Analytics for COVID-19
Aetion has announced the launch of their Roche-powered Population Level Analytics for COVID-19. This new tool enables users to analyze [...]
Unaddressed Behavioral Health Costs $68 Billion Annually
Up to 6.2 times more is spent on healthcare costs for populations with behavioral health conditions and medical comorbidities. Almost none of [...]
ICER to Assess Alzheimer’s Treatment
Today the Institute for Clinical and Economic Review (ICER) announced that it will assess the comparative clinical effectiveness and value [...]
Toward Transparency in Real-World Evidence Studies
Due to the funding or execution of studies by industry stakeholders and disagreements over methodological approaches, establishing and maintaining trust [...]
ISPOR Introduces New Competencies Framework for HEOR Professionals
In HEOR, the types of jobs and diversity of topics in which professionals must demonstrate competence is constantly evolving. To [...]
Explore health care innovations with UPenn’s Zeke Emanuel and other experts.
What makes healthcare innovation efforts succeed—or fail? Join leading policymaker and influential advisor Zeke Emanuel as he presents videos, case [...]
How Can a Safe and Effective COVID‑19 Vaccine be Allocated?
A number of serious challenges exist for universal vaccination campaigns, yet manufacturers remain undeterred. AstraZeneca intends to distribute a COVID-19 [...]
ICER Embarks on Annual Assessment of Insurance Coverage
The Institute for Clinical and Economic Review (ICER) is holding a review of current coverage policies of US insurers and [...]
ICER Publishes White Paper on Fair Patient Access to Prescription Drugs
The Institute for Clinical and Economic Review (ICER) published a new white paper entitled: "Cornerstones of 'Fair' Drug Coverage: Appropriate [...]
Educating the Next Leaders in Applied HEOR: Jefferson’s Unique Approach
Online education for the working professional is experiencing exponential growth. In the field of Health Economics and Outcomes Research (HEOR), [...]
[Webinar] How Can Adaptive Designs and Master Protocols Enhance Your Oncology Trials?
While oncology trials comprise a large proportion of current research pipelines, conventional oncology development programs are frequently expensive, inefficient, and [...]
ICER Condemns Monopoly Pricing of Trikafta Despite High Marks for Efficacy
While the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis is indisputable, the Institute for Clinical and [...]